The Latest Breaking News from Novo Nordisk

People with diabetes on semaglutide, found in Wegovy and Ozempic, four times more likely to be diagnosed with disease of optic nerve

US study says patients could have higher risk of developing NAION

As Nvidia tests support, Amazon breaks out and Meta moves toward a new buy point, IBD Leaderboard highlights more breakouts.

The S&P 500 and Nasdaq hit fresh all-time highs. Software, small caps and megacaps were stock market standouts.

The recent announcement that China approved Novo Nordisk's Wegovy is huge. Here's why: In a national survey conducted during 2015-2019 by China’s National Health Commission, more than half of the adult population was either overweight or obese. That's a massive market that just opened up for NVO.

Novo Nordisk's China patent on Wegovy's active ingredient expires in 2026, much earlier than its patents in the U.S., Japan and Europe.

Futures were mixed Wednesday, but Tesla rival Rivian vaulted higher on a big investment. FedEx jumped after earnings. Nvidia extended Monday's bounce.

Alternatives to costly Wegovy and Saxenda will make such treatments more widely available worldwide

The major indexes were mixed Tuesday as Nvidia and AI stocks rebounded. Novo Nordisk flashed a buy signal as its weight-loss drug Wegovy won China approval. Tesla is recalling the Cybertruck.